Notice of Closed Meeting, 8682 [2024-02514]
Download as PDF
<![CDATA[
8682
Federal Register / Vol. 89, No. 27 / Thursday, February 8, 2024 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to 5 U.S.C. 1009(d), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended, and the Determination of
the Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, CDC, pursuant to Public Law
92–463. The grant applications and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
DP24–031, Epidemiologic Cohort Study
of Interstitial Cystitis.
Date: April 10, 2024.
Time: 10 a.m.–6 p.m., EDT.
Place: Teleconference/Web
Conference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Catherine Barrett, Ph.D., Scientific
Review Officer, National Center for
Chronic Disease Prevention and Health
Promotion, Centers for Disease Control
and Prevention, 4770 Buford Highway,
Mailstop S106–3, Atlanta, Georgia
30341–3717. Telephone: (404) 718–
7664; Email: CBarrett@cdc.gov.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–02514 Filed 2–7–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket Nos. FDA–2023–N–2894; FDA–
2023–N–1929; FDA–2017–N–5569; FDA–
2023–N–2564; FDA–2023–N–2851; FDA–
2023–N–1554]
ACTION:
Notice.
The Food and Drug
Administration (FDA) is publishing a
list of information collections that have
been approved by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Amber Sanford, Office of Operations,
Food and Drug Administration, Three
White Flint North, 10A–12M, 11601
Landsdown St., North Bethesda, MD
20852, 301–796–8867, PRAStaff@
fda.hhs.gov.
The
following is a list of FDA information
collections recently approved by OMB
under section 3507 of the Paperwork
Reduction Act of 1995 (44 U.S.C. 3507).
The OMB control number and
expiration date of OMB approval for
each information collection are shown
in table 1. Copies of the supporting
statements for the information
collections are available on the internet
at https://www.reginfo.gov/public/do/
PRAMain. An Agency may not conduct
or sponsor, and a person is not required
to respond to, a collection of
information unless it displays a
currently valid OMB control number.
SUPPLEMENTARY INFORMATION:
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approvals
AGENCY:
Food and Drug Administration,
HHS.
TABLE 1—LIST OF INFORMATION COLLECTIONS APPROVED BY OMB
Title of collection
OMB control No.
Good Laboratory Practice (GLP) Regulations for Nonclinical Laboratory Studies .........................................
Orphan Drugs ..................................................................................................................................................
Medical Devices; Device Tracking ..................................................................................................................
Channels of Trade Policy for Commodities with Residues of Pesticide Chemicals for Which Tolerances
Have Been Revoked, Suspended, or Modified by the EPA ........................................................................
Time and Extent Applications for Nonprescription Drug Products ..................................................................
Qualitative Feedback on Food and Drug Administration Service Delivery .....................................................
Dated: February 5, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024–02579 Filed 2–7–24; 8:45 am]
lotter on DSK11XQN23PROD with NOTICES1
BILLING CODE 4164–01–P
VerDate Sep<11>2014
17:34 Feb 07, 2024
Jkt 262001
PO 00000
Frm 00042
Fmt 4703
Sfmt 9990
E:\FR\FM\08FEN1.SGM
08FEN1
Date approval
expires
0910–0119
0910–0167
0910–0442
1/31/2027
1/31/2027
1/31/2027
0910–0562
0910–0688
0910–0697
1/31/2027
1/31/2027
1/31/2027
]]>Agencies
[Federal Register Volume 89, Number 27 (Thursday, February 8, 2024)]
[Notices]
[Page 8682]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-02514]
[[Page 8682]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the
following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended, and the Determination of the Director, Office of
Strategic Business Initiatives, Office of the Chief Operating Officer,
CDC, pursuant to Public Law 92-463. The grant applications and the
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)--DP24-031, Epidemiologic Cohort
Study of Interstitial Cystitis.
Date: April 10, 2024.
Time: 10 a.m.-6 p.m., EDT.
Place: Teleconference/Web Conference.
Agenda: To review and evaluate grant applications.
For Further Information Contact: Catherine Barrett, Ph.D.,
Scientific Review Officer, National Center for Chronic Disease
Prevention and Health Promotion, Centers for Disease Control and
Prevention, 4770 Buford Highway, Mailstop S106-3, Atlanta, Georgia
30341-3717. Telephone: (404) 718-7664; Email: [email protected].
The Director, Office of Strategic Business Initiatives, Office of
the Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-02514 Filed 2-7-24; 8:45 am]
BILLING CODE 4163-18-P
